Bristol-Myers Will Divest Celgene Blockbuster to Close Deal
A deal may not always be the best prescription. (Photographer: George Frey/Bloomberg)

Bristol-Myers Will Divest Celgene Blockbuster to Close Deal

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to divest one of Celgene Corp.’s most lucrative drugs in order to close their planned $74 billion merger.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.